Company news

Quince Therapeutics, Inc. news in 2026

Quince Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

October 9, 2026

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

September 17, 2026

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026

Quince Therapeutics Settles Approximately $16.4 Million of Debt

March 29, 2026

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

February 9, 2026

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

January 29, 2026

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

January 28, 2026

Decks in 2026